ConjugateBio

ConjugateBio is a privately held, venture-backed biotechnology company founded in 2022, headquartered in Princeton, New Jersey, USA. The company is currently advancing a series of First-in-Class (FIC) Antibody-Drug Conjugates (ADCs) in stealth mode, targeting solid tumors with high unmet medical needs. By combining licensed and internally innovative antibodies with proprietary linker-payload technology, ConjugateBio is building a robust portfolio aimed at treating cancers ranging from ultra-rare diseases to the most common malignancies.